ADHD Drug Treatment Reduces Risks of Suicidal Behaviors, Substance Misuse, and Criminality
By
bookofjoe
Toasted golden, schmeared with insight. Top of the rack.
Summary
The study examines the effects of ADHD drug treatment on risks of suicidal behaviors, substance misuse, accidental injuries, transport accidents, and criminality. Using Swedish national register data from 2007-2020, the research emulated target trials involving 148,581 individuals with ADHD. Results showed that drug treatment significantly reduced rates of suicidal behaviors, substance misuse, transport accidents, and criminality, with more pronounced effects for recurrent events. No significant reduction was observed for accidental injuries. The findings highlight the benefits of ADHD medication in mitigating these risks, particularly for individuals with prior incidents.
Key quotes
· 4 pulledDrug treatment for ADHD was associated with reduced rates of the first occurrence of suicidal behaviours (weighted incidence rates 14.5 per 1000 person years in the initiation group versus 16.9 in the non-initiation group).
The reduced rates were more pronounced among individuals with previous events, with incidence rate ratios ranging from 0.79 (0.72 to 0.86) for suicidal behaviours to 0.97 (0.93 to 1.00) for accidental injuries.
For recurrent events, drug treatment for ADHD was significantly associated with reduced rates of all five outcomes, with incidence rate ratios of 0.85 (0.77 to 0.93) for suicidal behaviours, 0.75 (0.72 to 0.78) for substance misuse.
This target trial emulation study using national register data provides evidence that is representative of patients in routine clinical settings.
You might also wanna read
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
